These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 8031320

  • 1. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein.
    Hatzelmann A, Goossens J, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R.
    Biochem Pharmacol; 1994 Jun 15; 47(12):2259-68. PubMed ID: 8031320
    [Abstract] [Full Text] [Related]

  • 2. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds.
    Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R.
    Biochem Pharmacol; 1993 Jan 07; 45(1):101-11. PubMed ID: 8381000
    [Abstract] [Full Text] [Related]

  • 3. Ca2+ ionophore A23187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene B4.
    Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R.
    Biochem Pharmacol; 1994 Jul 05; 48(1):31-9. PubMed ID: 8043028
    [Abstract] [Full Text] [Related]

  • 4. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase.
    Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Matzke M, Pleiss U, Keldenich J, Müller-Peddinghaus R.
    Agents Actions; 1994 Nov 05; 43(1-2):64-8. PubMed ID: 7741044
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological modulation of human platelet leukotriene C4-synthase.
    Sala A, Folco G, Henson PM, Murphy RC.
    Biochem Pharmacol; 1997 Mar 21; 53(6):905-8. PubMed ID: 9113110
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005.
    Gardiner PJ, Cuthbert NJ, Francis HP, Fitzgerald MF, Thompson AM, Carpenter TG, Patel UP, Newton BB, Mohrs K, Müller-Peddinghaus R.
    Eur J Pharmacol; 1994 Jun 02; 258(1-2):95-102. PubMed ID: 7925604
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.
    Charleson S, Prasit P, Léger S, Gillard JW, Vickers PJ, Mancini JA, Charleson P, Guay J, Ford-Hutchinson AW, Evans JF.
    Mol Pharmacol; 1992 May 02; 41(5):873-9. PubMed ID: 1588922
    [Abstract] [Full Text] [Related]

  • 12. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
    Brideau C, Chan C, Charleson S, Denis D, Evans JF, Ford-Hutchinson AW, Fortin R, Gillard JW, Guay J, Guévremont D.
    Can J Physiol Pharmacol; 1992 Jun 02; 70(6):799-807. PubMed ID: 1330258
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity.
    Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon HP, Safayhi H.
    Br J Pharmacol; 1996 Feb 02; 117(4):615-8. PubMed ID: 8646405
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor.
    Hofmann B, Rödl CB, Kahnt AS, Maier TJ, Michel AA, Hoffmann M, Rau O, Awwad K, Pellowska M, Wurglics M, Wacker M, Zivković A, Fleming I, Schubert-Zsilavecz M, Stark H, Schneider G, Steinhilber D.
    Br J Pharmacol; 2012 Apr 02; 165(7):2304-13. PubMed ID: 21955369
    [Abstract] [Full Text] [Related]

  • 18. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
    Carty TJ, Sweeney FJ, Griffiths RJ, Eskra JD, Ernest MJ, Pillar JS, Cheng JD, Loose LD, Joseph PA, Pazoles PP, Moore PF, Nagahisa A, Murase S, Kadin SB.
    Inflamm Res; 1997 May 02; 46(5):168-79. PubMed ID: 9197987
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.